Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) received clearance from the U.S. Food and Drug Administration on April 30, 2026 for its investigational new drug (IND) application for Telomir‑Zn, a small‑molecule therapy that targets triple‑negative breast cancer (TNBC). The approval removes a major regulatory hurdle and allows the company to begin a first‑in‑human Phase 1/2 study in the first half of 2026 at a leading U.S. academic medical center.
The IND clearance marks a pivotal transition for Telomir, moving it from a pre‑clinical biotech with no revenue to a clinical‑stage company. It also unlocks milestone‑based funding from the company’s recent merger with TELI Pharmaceuticals, which provides up to $5 million in total—$1 million at closing and up to $4 million in milestone‑based contributions tied to IND acceptance and Phase 1/2 initiation, of which $2 million is milestone‑based. This funding, combined with the company’s strong liquidity (current ratio 5.14) and a runway that supports operations through early 2027, positions Telomir to generate data that could attract partnership interest and potentially shift its valuation.
The Phase 1/2 study, designated TELO‑001, will enroll approximately 76 patients with advanced or metastatic TNBC. The protocol includes dose‑escalation and expansion phases, with primary endpoints of safety, tolerability, pharmacokinetics, and pharmacodynamics, and secondary endpoints of preliminary antitumor activity. Integrated biomarker analyses will assess the drug’s impact on intracellular metal balance and epigenetic regulation, the core mechanism that differentiates Telomir‑Zn from existing therapies.
Telomir’s platform is built on the modulation of intracellular metal balance—specifically iron and zinc—to disrupt epigenetic vulnerabilities in tumor cells. Preclinical data demonstrate tumor growth suppression and enhanced activity when combined with chemotherapy in TNBC models, though responses vary across models, underscoring the need for clinical validation. The company’s acquisition of TELI on April 24, 2026 consolidated global rights to Telomir‑1 (Telomir‑Zn) and secured the milestone funding that now supports the IND clearance and upcoming trial.
CEO Erez Aminov said, "The clearance of our IND, including the Phase 1/2 clinical protocol, marks an important step as we advance Telomir‑Zn into clinical evaluation." Chief Scientific Advisor Dr. Itzchak Angel added, "Telomir‑Zn is designed to target fundamental aspects of tumor biology through modulation of intracellular metal balance and epigenetic regulation. This metal‑epigenetic approach represents a differentiated therapeutic strategy that may have relevance not only in triple‑negative breast cancer but also across broader cancer and age‑related disease biology."
The FDA clearance signals that Telomir’s preclinical safety and efficacy data met the agency’s standards for human studies, validating its metal‑modulation platform and opening a $300 billion addressable market that extends beyond TNBC. The milestone also positions Telomir to pursue partnership talks, unlock additional milestone funding, and potentially shift its valuation as it moves into the clinical phase. The company’s next steps will involve patient enrollment, safety monitoring, and early efficacy signal collection, all of which will be closely watched by investors and potential collaborators.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.